Loading...
Guaifenesin — Export Intelligence Report
2025-Q4 · TransData Nexus
PHARMA TRADE INTELLIGENCE
INDIA EXPORT INTELLIGENCE REPORT
Guaifenesin
2025-Q4
Comprehensive analysis of India’s guaifenesin export trade — suppliers, buyers, prices, routes, and every shipment record.
48
Shipments
$1.18M
Trade Value
13
Suppliers
17
Buyers
9
Countries
Scan for online report
Talk to our analyst: +91 95950 78788
https://transdatanexus.com/pharmaceutical/guaifenesin
01
PART I — OVERVIEW
Executive Summary
At-a-glance KPIs, key findings, and strategic positioning of India’s guaifenesin trade — 2025-Q4
KEY TAKEAWAY
Guaifenesin 2025-Q4 exports total $1.2M across 9 countries, with GRANULES INDIA LTD commanding 40.4% market share.
TOTAL SHIPMENTS
48
2025-Q4
EXPORT VALUE
$1.2M
FOB USD
TOTAL QUANTITY
17.7M
units shipped
INDIAN SUPPLIERS
13
unique exporters
GLOBAL BUYERS
17
unique importers
DESTINATIONS
9
countries
MEDIAN UNIT PRICE
$0.671
per unit
TOP-5 SHARE
93.2%
of total USD
BRANDED SHARE
41.7%
20 shipments
DOSAGE FORMS
8
product types
6 KEY FINDINGS
1
GRANULES INDIA LTD is India's #1 Guaifenesin exporter with $477.8K (40.4% market share).→ §5, Indian Supplier Rankings
2
Guaifenesin reached 9 countries, with United States as the top destination ($1.1M).→ §4, Global Destination Map
3
Market concentration is high (HHI: 2564) — top 10 suppliers control 99.8% of exports.→ §5, Indian Supplier Rankings
4
94.1% of buyers (16 of 17) source from a single Indian supplier — potential poaching opportunities.→ §6, Global Buyer Rankings
5
Tablet dominates (68.7%) across 8 dosage forms.→ §7, Price Benchmarks
6
8 countries have ≤5 Indian suppliers — easy-entry markets for SME exporters.→ §9, Strategic Opportunities
WHO THIS REPORT IS FOR
S SUPPLIERS (Indian pharma exporters)
- See which buyers your competitors are shipping to, at what price, through which ports
- Identify buyers that are single-sourced (poaching opportunities)
- Benchmark your pricing and catalog vs the Top 25
B BUYERS (global importers)
- Discover which Indian exporters supply this product and what they sell
- Benchmark the price you are paying vs the market median by country and dosage
- Identify alternative suppliers with proven exports to similar destinations
Figure 1.1 GRANULES INDIA LTD leads in volume — how do 13 exporters compare on price × volume?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Every bubble is one Indian guaifenesin exporter. X-axis = shipment count; Y-axis = average unit price; bubble size = total revenue. Dashed lines split at the median — exporters in the top-right (Bulk Leaders) combine high volume with premium pricing.
HOW TO READ THIS REPORT
60 seconds
Scan this page — KPIs, thesis, flagship chart, top findings
5 minutes
Read every Key Takeaway line across §1–§9
30 minutes
Read sections tagged for your role ([S] or [B]) end-to-end
In depth
Drill into §10 for your country · supplier / buyer directories at end
02
PART I — OVERVIEW
About This Report
Data sources, methodology, trust signals, and what this Guaifenesin report covers
KEY TAKEAWAY
Every figure in this report is grounded in real commercial guaifenesin trade records. Data comes from official customs filings and public trade sources, runs through a multi-layer quality process, and lands in a clean, consistent report you can rely on.
S FOR SUPPLIERS
Every competitor benchmark, market share figure, and buyer list in this report comes from verified commercial shipments — not surveys or estimates. Use them with confidence when planning your next pitch.
B FOR BUYERS
Every supplier profile, price benchmark, and trade route in this report reflects what that supplier actually ships — real volumes, real destinations, real prices. Use them to qualify and compare Indian guaifenesin suppliers.
§2.1 Reporting parameters · the scope of this 2025-Q4 Guaifenesin India trade report
Product scope
Guaifenesin
All variants merged — branded and generic formulations of guaifenesin
Time period
2025-Q4
October, November, December 2025 — a single-quarter snapshot
Data sources
Official & public trade records
Government customs filings, public trade databases and licensed commercial feeds
Geography
India origin → global
Indian sea and air ports shipping to destination markets worldwide
Currency
USD (FOB)
Declared Free-on-Board value at the Indian port of loading
Shipments analysed
48
Every commercial guaifenesin trade record in the period, aggregated and deduplicated
§2.2 Our quality process · Figure 2.1
Figure 2.1 From raw trade records to a clean report — the four quality pillars.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Raw trade data (left) flows through four quality checks — source verification, format standardisation, entity matching, and deduplication — to produce the clean, reliable data (right) behind every chart and table in this report.
§2.3 Trust signals · what you can rely on in the numbers you read
DATA COVERAGE
10M+
Pharmaceutical trade records across the full TransData Nexus platform.
COUNTRIES
150+
Origin and destination countries covered in the global pharma trade database.
DATA ACCURACY
99.9%
Validation rate on core fields — supplier, buyer, product, quantity, value.
UPDATE FREQUENCY
Daily
Platform refresh cadence. This report is a snapshot from the same live data.
§2.4 Limitations · what the data does and does not tell you
WHAT THIS DATA DOES AND DOES NOT SAY
- Prices are at the Indian port of loading (FOB), not the final delivered cost in the destination country. Freight, insurance, import duty and local margin are not included.
- This is a single-quarter snapshot. Multi-quarter trends, year-over-year growth and historical comparisons are available on the full platform.
- A small number of records have incomplete transport mode or destination port fields; these appear blank in the shipment register but are still counted in totals.
- This report is a commercial intelligence tool, not a legal audit. For high-stakes decisions, cross-reference with the underlying trade records via the full platform.
03
PART II — MARKET STRUCTURE
Quarterly Trade Overview
Monthly trends, regional performance, and ranking shifts — 2025-Q4
KEY TAKEAWAY
2025-Q4 followed a steady rise: Oct $260.9K, Nov $363.9K, Dec $556.6K. Shipment counts were mixed across the quarter.
S FOR SUPPLIERS
Track which months your competitors were most active, which destinations rose or fell, and whether the Nov dip hit your segment. The bump charts show rank movement — watch for rivals climbing past you.
B FOR BUYERS
Identify whether your current Indian supplier maintained steady shipments through the quarter, or whether they pulled back. Steady suppliers during dips signal reliable partnerships.
1
$260.9K
Oct USD
17 shipments
2
$363.9K
Nov USD
+39.5% MoM
3
$556.6K
Dec USD
+52.9% MoM
4
Steady rise
Q4 growth shape
Oct → Nov → Dec
Fig 3.1 Nov rose 39.5% in USD but shipment count kept steady.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Blue bars = monthly USD. Orange line = shipment count. When bars drop but line rises, average shipment value fell. Insight: Oct opened at $261K, making it the weakest month by value.
Fig 3.2 Q4 cumulative USD reached $1.2M.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: The curve shows the running total across the quarter. A steeper slope means that month contributed more revenue. Insight: The curve’s steepest section reveals which month drove the most trade value.
Fig 3.3 $103K rise in Nov, $193K recovery in Dec.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Blue bars = absolute monthly value. Red = month-over-month loss; green = gain. Insight: Trade grew steadily across the quarter.
Fig 3.4 Regional breakdown by month — which corridors swung most?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each coloured layer is one destination region. Layer height = USD in that month. Insight: The top region contributed the most, while the smallest region had the least volume.
§3.1 Monthly summary
| Oct | $261K | 17 shipments |
| Nov | $364K | 16 shipments |
| Dec | $557K | 15 shipments |
| Q4 Total | $1.2M | 48 shipments |
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
Fig 3.5 Top 9 destination countries by monthly USD rank — who’s rising?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each line traces a country’s monthly rank. Lines crossing = rank swaps. Insight: United States held #1 throughout the quarter.
Fig 3.6 Top 10 Indian exporters by monthly USD rank.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each line traces a supplier’s monthly rank. Flat = stable position; crossing = rank change. Insight: MARKSANS PHARMA LTD maintained its leading position.
04
PART II — MARKET STRUCTURE
Global Destination Map
Which countries import guaifenesin from India, how much they buy, and who supplies each market
KEY TAKEAWAY
United States absorbs 94.0% of India’s 2025-Q4 guaifenesin trade ($1.1M). Beyond the top 9 destinations, 8 countries have fewer than 5 Indian suppliers each — white-space markets where new entrants face minimal competition. Asia has 5 destination countries, the widest regional diversity.
S FOR SUPPLIERS
Use the flow map and lanes table to see which destinations your competitors dominate. For small and mid-size suppliers: look beyond the leading markets — the 8 countries in the long tail have fewer than 5 Indian suppliers each and low competitive barriers.
B FOR BUYERS
Find your country on the map to see how much guaifenesin India ships to your market, who the top suppliers are, and whether you’re in a concentrated or competitive corridor.
Asia
$9K
0.8% of trade
5 countries · 7 shipments
Europe
$11K
1.0% of trade
1 countries · 1 shipments
Americas
$1.1M
94.0% of trade
1 countries · 36 shipments
Africa
$51K
4.3% of trade
2 countries · 4 shipments
Fig 4.1 United States is the #1 corridor ($1.1M) — 9 flow arcs from India radiate across 4 continents.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: The world map shows every country colored by how much Indian guaifenesin it receives (light = low, dark = high). Orange arcs radiate from India to the top 9 destinations; arc thickness = USD value. All destinations are labeled with country name + USD.
§4.1 Top 9 bilateral trade lanes (India → destination) with top Indian suppliers
| # | Destination | Total USD | Ships | #1 Indian supplier | USD | #2 Indian supplier | USD | #3 Indian supplier | USD |
|---|---|---|---|---|---|---|---|---|---|
| 1 | United States | $1.1M | 36 | GRANULES INDIA LTD | $478K | ELYSIUM PHARMACEUTICALS LTD | $278K | MARKSANS PHARMA LTD | $199K |
| 2 | Tanzania | $33K | 1 | CADILA PHARMACEUTICALS LTD | $33K | — | — | — | — |
| 3 | Senegal | $18K | 3 | ALFA BIOMED INDIA PVT LTD | $18K | — | — | — | — |
| 4 | France | $11K | 1 | ALFA BIOMED INDIA PVT LTD | $11K | — | — | — | — |
| 5 | Tajikistan | $3K | 1 | XIEON LIFE SCIENCES PVT LTD | $3K | — | — | — | — |
| 6 | United Arab Emirates | $3K | 1 | JOINHUB PHARMA LLP | $3K | — | — | — | — |
| 7 | Afghanistan | $2K | 1 | LABORATE PHARMACEUTICALS INDIA LTD | $2K | — | — | — | — |
| 8 | Singapore | $165 | 1 | SANITAS MEDTECH INSTITUTE PVT LTD | $165 | — | — | — | — |
| 9 | Maldives | $0 | 3 | MOTHER INDIA TRADERS | $0 | — | — | — | — |
Table 4.1 — Top 9 destination countries ranked by trade value, with the largest Indian suppliers for each market.
Fig 4.2 Asia leads at 0.8% of USD — but United States is the single largest market.
Region → country treemap
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Column width = region USD share. Within each column, cells are stacked by country, height = share within region.
§4.2 Destination concentration
94.0%
#1 country share
United States alone
99.5%
Top 5 share
5 of 9 countries
100.0%
Top 15 share
Long tail of -6 countries = -0.0%
HHI 8838
Destination HHI
Highly concentrated
9
Countries served
Global pharma reach from India
5
Asia countries
Widest regional diversity
Source: TransData Nexus trade data platform
05
PART III — WHO’S IN THIS MARKET
Indian Supplier Rankings & Profiles
13 Indian exporters ranked by value — profiles, portfolios, and competitive intelligence
KEY TAKEAWAY
GRANULES INDIA LTD ($477.8K, 40.4% share) and ELYSIUM PHARMACEUTICALS LTD ($278.1K) together control 64.0% of India’s 2025-Q4 guaifenesin trade. The top 5 suppliers hold 93.2%. 13 companies shipped at least once.
S FOR SUPPLIERS
Find your rank, your competitors’ ranks, and the gap in USD/share between you. The profile pages show each top supplier’s buyer portfolio, dosage mix and route map — your competitive-intelligence toolkit.
B FOR BUYERS
Find potential Indian guaifenesin suppliers ranked by size, catalog breadth and destination reach. The profile pages reveal which suppliers have proven trade lanes to your region.
Fig 5.1 GRANULES INDIA LTD leads by $200K over ELYSIUM PHARMACEUTICALS LTD — top 13 Indian exporters ranked by trade value
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one Indian supplier ranked by USD. The (#N) shows their rank by shipment count — mismatches reveal pricing strategy. Insight: MOTHER INDIA TRADERS is #13 by value but #7 by volume.
Fig 5.2 MARKSANS PHARMA LTD also leads by shipment count (12) but ranking shifts for volume-heavy players
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Same suppliers re-ranked by shipment count. The (#N) shows their rank by USD value. Insight: MOTHER INDIA TRADERS moves from #7 by volume to #13 by value — fewer but higher-value shipments.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — Archetypes & Concentration
How India’s 13 guaifenesin suppliers split into strategic segments
KEY TAKEAWAY
4 suppliers (25%) generate 87.6% of total trade value. The market splits into four archetypes: Market Leaders, High-Value specialists, Volume players, and a long tail.
Fig 5.3 GRANULES INDIA LTD and ELYSIUM PHARMACEUTICALS LTD sit in the leaders zone — high volume AND high value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bubble is one Indian supplier. X-axis = shipment count (log scale); Y-axis = total USD value (log scale); bubble size = revenue. Blue dashed lines split at the median. Market Leaders (top-right) combine high volume with high value. Premium Niche (top-left) ship fewer but higher-value consignments. Volume Players (bottom-right) compete on quantity. Long-Tail (bottom-left) are small or occasional exporters. Conclusion: the log scale reveals clear strategic clusters — use this map to identify where your company sits relative to competitors.
Fig 5.4 25% of suppliers = 87.6% of USD — classic concentration.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Top bar = supplier %, bottom bar = USD %. The gap = market concentration.
Product variety — how many formulations each supplier ships
| # | Supplier | Dosage forms | Countries | USD |
|---|---|---|---|---|
| 1 | ELYSIUM PHARMACEUTICALS LTD | 2 | 1 | $278K |
| 2 | MARKSANS PHARMA LTD | 2 | 1 | $199K |
| 3 | SUN PHARMACEUTICAL INDUSTRIES LTD | 2 | 1 | $66K |
| 4 | ALFA BIOMED INDIA PVT LTD | 2 | 2 | $30K |
| 5 | GRANULES INDIA LTD | 1 | 1 | $478K |
| 6 | DRREDDYS LABORATORIES LTD | 1 | 1 | $81K |
| 7 | CADILA PHARMACEUTICALS LTD | 1 | 1 | $33K |
| 8 | KJD PHARMA PVT LTD | 1 | 1 | $9K |
| 9 | XIEON LIFE SCIENCES PVT LTD | 1 | 1 | $3K |
| 10 | JOINHUB PHARMA LLP | 1 | 1 | $3K |
Table 5.1 — The more dosage forms a supplier ships, the more versatile their manufacturing capability.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — India Origin Geography & Concentration
Which Indian cities and states are the guaifenesin manufacturing hubs
KEY TAKEAWAY
Hyderabad and Dist. Vadodara together account for $756K of India’s 2025-Q4 guaifenesin trade.
Fig 5.5 Hyderabad (1 exporters, $478K) and Dist. Vadodara (1 exporters, $278K) are India’s guaifenesin capitals.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Orange bubbles mark major pharma hub cities; bubble size = USD value. Every hub labeled.
§5.1 Supplier concentration metrics
93.2%
Top 5 share
5 of 13 suppliers
99.8%
Top 10 share
10 of 13 suppliers
87.6%
Top 25% share
4 suppliers = 88% USD
HHI 2564
Supplier HHI
Concentrated
13
Total suppliers
shipped Guaifenesin in 2025-Q4
13+ cities
Indian hubs
Hyderabad and Dist. Vadodara lead
§5.2 Coming next: 0 exporter deep-dive profiles
Each of the top 0 suppliers gets a dedicated 2-page profile with:
- 6 KPI cards — trade value, shipments, countries, buyers, avg ship value, branded share
- Dosage form breakdown — what formulations they ship
- Monthly trend — Oct / Nov / Dec trajectory
- Trade flow map — supplier → country → importer connections
- Buyer portfolio with lock-in analysis
SUPPLIER PROFILES IN THIS REPORT
06
PART III — WHO’S IN THIS MARKET
Global Buyer Rankings & Intelligence
17 importers across 9 countries — who is buying Indian guaifenesin and how much
KEY TAKEAWAY
The demand side is dramatically more fragmented than supply: the top 16 importers together hold only 99.2% of total USD. 94% of buyers source from a single Indian supplier — a vast pool of lock-in candidates.
S FOR SUPPLIERS
Find the importers buying from your competitors. The rankings reveal who has volume, who pays well, and who sources from multiple Indian suppliers (potential pitch targets).
B FOR BUYERS
See where you rank among global importers of Indian guaifenesin. Compare your USD and shipment count against peers in your country and dosage segment.
Fig 6.1 GRANULES USA is the #1 importer at $343K (29.1%) — top 16 by trade value
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one global importer ranked by USD.
Fig 6.2 Re-ranked by shipment count — compare with Fig 6.1 for divergences
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Same 16 importers re-ranked by shipment count.
§6.1 Sourcing diversity — how many Indian suppliers does each buyer use?
94%
Single-source
16 buyers rely on exactly 1 Indian supplier
0%
Dual-source
0 buyers use 2 Indian suppliers
6%
Multi-source (3–4)
1 buyers diversified across 3–4
0%
Broad-source (5+)
0 buyers with 5+ Indian suppliers
06
PART III — WHO’S IN THIS MARKET
Single-Source Buyers & Price Benchmark
Lock-in opportunities grouped by country + where each buyer sits on the price spectrum
KEY TAKEAWAY
These importers source guaifenesin from exactly one Indian supplier. For each one, the table shows the incumbent, price, and dosage.
S FOR SUPPLIERS
This is your target list. Each row is a buyer locked into one competitor. Offer 5–10% better pricing to win the second-source slot.
B FOR BUYERS
If you see your company here, you are fully dependent on one Indian supplier. Consider qualifying a second source.
§6.2 Single-source lock-in by country
United States 5 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| GRANULES USA | GRANULES INDIA LTD | $343K | $0.040 | Tablet |
| TIME-CAP LABS INC | MARKSANS PHARMA LTD | $176K | $1.742 | Tablet |
| HHH PHARMACEUTICALS | ELYSIUM PHARMACEUTIC… | $164K | $306.793 | Tablet |
| GRANULES CONSUMER HEAL… | GRANULES INDIA LTD | $134K | $0.024 | Tablet |
| PRODOSE INC | ELYSIUM PHARMACEUTIC… | $93K | $327.531 | — |
Tanzania 1 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| YASH PHARMACEUTICALS LTD | CADILA PHARMACEUTICA… | $33K | $0.739 | expectorant |
Senegal 1 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| DUOPHARM | ALFA BIOMED INDIA PV… | $18K | $0.087 | Suspension |
France 1 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| PLANET PHARMAZAC DU GR… | ALFA BIOMED INDIA PV… | $11K | $0.233 | Tablet |
Singapore 1 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| SUCCESS INTER LINK PTE… | SANITAS MEDTECH INST… | $164.882 | $8.244 | Tablet |
§6.3 Price positioning — top 16 importers
| # | Importer | Country | USD | $/ship | Tier |
|---|---|---|---|---|---|
| 1 | GRANULES USA | United States | $343K | $86K | Premium |
| 2 | TIME-CAP LABS INC | United States | $176K | $18K | Mid |
| 3 | HHH PHARMACEUTICALS | United States | $164K | $82K | Premium |
| 4 | GRANULES CONSUMER HE… | United States | $134K | $45K | Premium |
| 5 | PRODOSE INC | United States | $93K | $46K | Premium |
| 6 | REED-LANE INC | United States | $81K | $81K | Premium |
| 7 | OHM LABORATORIES INC | United States | $66K | $13K | Budget |
| 8 | YASH PHARMACEUTICALS… | Tanzania | $33K | $33K | Mid |
| 9 | TIME-CAP LABSINC 7 M… | United States | $23K | $12K | Budget |
| 10 | PIONEER LIFE SCIENCE… | United States | $21K | $21K | Mid |
| 11 | DUOPHARM | Senegal | $18K | $6K | Budget |
| 12 | PLANET PHARMAZAC DU … | France | $11K | $11K | Budget |
| 13 | AIRLIE PHARMA | United States | $9K | $2K | Budget |
| 14 | SUCCESS INTER LINK P… | Singapore | $164.882 | $165.000 | Budget |
| 15 | AGALU | Maldives | $0.0000 | $0.0000 | Budget |
| 16 | K.D.M SHOP NO .01 (BN | Maldives | $0.0000 | $0.0000 | Budget |
06
PART III — WHO’S IN THIS MARKET
Market Relationship Map
The top 13 × 16 supplier ↔ buyer network as a circular flow diagram
Fig 6.3 GRANULES INDIA LTD → GRANULES USA is the strongest relationship.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left semicircle = top 13 Indian suppliers; right = top 16 global buyers. Arc length = total USD; colored ribbons = individual relationships, thickness = USD value. Insight: follow the thickest ribbons to identify the dominant trading pairs.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
How Indian guaifenesin prices vary by supplier, country and dosage form
KEY TAKEAWAY
Guaifenesin prices span 14677× ($0.023 → $333.25). The coefficient of variation is 2.73. Dosage form, not destination, is the primary price driver.
S FOR SUPPLIERS
Use the box plot to see where your product sits on the price spectrum. The tornado chart shows exactly where you sit relative to the market median.
B FOR BUYERS
Use this section to benchmark the price you pay against the market. The percentile strip tells you if your current supplier is charging you premium, mid-market or budget rates.
§7.1 Price distribution · Table 7.1
| Statistic | Value | Interpretation |
|---|---|---|
| Min | $0.023 | Lowest observed unit price |
| P5 | $0.024 | 5th percentile |
| P25 | $0.070 | 25th percentile (Q1) |
| Median | $0.671 | 50th percentile (Q2) |
| P75 | $2.33 | 75th percentile (Q3) |
| P95 | $322.32 | 95th percentile |
| Max | $333.25 | Highest observed unit price |
| Mean | $36.84 | Arithmetic average |
| CV | 273% | Coefficient of variation (std/mean) |
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
Fig 7.1 ELYSIUM PHARMACEUTICALS LTD prices at $320.94/unit vs market median $0.671.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar shows one supplier’s average unit price relative to the market median (dashed line). Red = above median (premium), green = below (budget).
COMMODITY KINGS
high volume · low unit price
Bulk API/tablet. Largest absolute USD despite lowest per-unit prices. e.g. GRANULES INDIA LTD Sourcing: best for cost-driven procurement.
BULK LEADERS
high volume · premium price
Branded-generic leaders, above-median pricing. e.g. ELYSIUM PHARMACEUTICALS LTD Sourcing: hardest to displace; compete on relationship.
LONG-TAIL
low volume · low unit price
Spot/opportunistic players. e.g. DRREDDYS LABORATORIES LTD Sourcing: first to approach for new tenders.
PREMIUM NICHE
low volume · premium price
Sterile injectables and infusions. Hospital-grade. e.g. CADILA PHARMACEUTICALS LTD Sourcing: expect 10× price vs tablet.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
Outlier forensics and the procurement cheat sheet — what to expect to pay by country × dosage
KEY TAKEAWAY
Extreme prices are real: the highest are specialty/sterile formulations; the lowest are bulk API. The cheat sheet matrix is the take-home reference for procurement teams.
§7.2 Outlier forensics — top 10 highest and 10 lowest unit prices
↑ TOP 10 HIGHEST USD/UNIT
| Date | Exporter | Country | Dosage | Qty | USD | $/unit | Why |
|---|---|---|---|---|---|---|---|
| Nov 2025 | ELYSIUM PHARMACE… | United States | — | 168 | $56K | $333.25 | Specialty / small-batch |
| Oct 2025 | ELYSIUM PHARMACE… | United States | Tablet | 64 | $21K | $327.49 | Specialty / small-batch |
| Oct 2025 | ELYSIUM PHARMACE… | United States | Tablet | 128 | $41K | $323.10 | Specialty / small-batch |
| Nov 2025 | ELYSIUM PHARMACE… | United States | — | 115 | $37K | $319.18 | Specialty / small-batch |
| Nov 2025 | ELYSIUM PHARMACE… | United States | Other | 408 | $123K | $301.68 | Specialty / small-batch |
| Nov 2025 | MARKSANS PHARMA … | United States | Tablet | 2K | $18K | $10.50 | Specialty / small-batch |
| Nov 2025 | SANITAS MEDTECH … | Singapore | Tablet | 20 | $164.88 | $8.24 | Specialty / small-batch |
| Dec 2025 | SUN PHARMACEUTIC… | United States | Tablet | 2K | $9K | $4.81 | Specialty / small-batch |
| Oct 2025 | MARKSANS PHARMA … | United States | Tablet | 3K | $14K | $4.18 | Specialty / small-batch |
| Dec 2025 | SUN PHARMACEUTIC… | United States | Tablet | 7K | $19K | $2.49 | Specialty / small-batch |
↓ TOP 10 LOWEST USD/UNIT
| Date | Exporter | Country | Dosage | Qty | USD | $/unit | Why |
|---|---|---|---|---|---|---|---|
| Dec 2025 | GRANULES INDIA LTD | United States | Tablet | 1.9M | $42K | $0.023 | Bulk volume discount |
| Dec 2025 | GRANULES INDIA LTD | United States | Tablet | 1.9M | $44K | $0.024 | Bulk volume discount |
| Dec 2025 | GRANULES INDIA LTD | United States | Tablet | 1.8M | $44K | $0.024 | Bulk volume discount |
| Dec 2025 | GRANULES INDIA LTD | United States | Tablet | 2.0M | $47K | $0.024 | Bulk volume discount |
| Dec 2025 | SUN PHARMACEUTIC… | United States | Tablet | 27K | $807.38 | $0.030 | |
| Dec 2025 | SUN PHARMACEUTIC… | United States | Tablet | 30K | $892.63 | $0.030 | |
| Oct 2025 | DRREDDYS LABORAT… | United States | Tablet | 2.2M | $81K | $0.037 | Bulk volume discount |
| Dec 2025 | GRANULES INDIA LTD | United States | Tablet | 1.9M | $84K | $0.044 | Bulk volume discount |
| Dec 2025 | GRANULES INDIA LTD | United States | Tablet | 980K | $43K | $0.044 | |
| Dec 2025 | GRANULES INDIA LTD | United States | Tablet | 3.8M | $174K | $0.045 | Bulk volume discount |
§7.3 Procurement cheat sheet — median USD/unit by country × dosage
Fig 7.2 Median unit price by country × dosage form — darker cells = higher prices.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each cell shows the median price per unit for that country-dosage combination. Dark blue = expensive, light = cheap. Blank cells = no shipments in that combination.
NEGOTIATION RANGE
Use each cell value as the anchor price. Typical dynamics:
- Budget buyer: anchor − 10–15% (floor = cost + freight)
- Mid-market: anchor ± 5–10%
- Premium/tender: anchor + 10–25% (regulated, quality premium)
- Injection/infusion: always 4–10× the tablet price
KEY TAKEAWAYS
- Dosage form is the #1 price driver, not destination
- Light cells = easy-entry markets for small suppliers
- Dark cells = premium markets requiring regulatory investment
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Which Indian ports ship guaifenesin, which global ports receive it, and which corridors are high-value vs bulk
KEY TAKEAWAY
Guaifenesin leaves India through 8+ ports. The top 5 (HYDERABAD ICD, MUNDRA SEA, NHAVA SHEVA SEA (JNPT)) handle 99.8% of total USD. ICD moves 33% of shipments.
S FOR SUPPLIERS
Use the dumbbell to classify your port as high-value hub or bulk workhorse. Note the short-sea routes — Bangladesh, Sri Lanka, Myanmar and East Africa are the easiest logistics corridors for first-time exporters.
B FOR BUYERS
Use the destination port ranking to find which Indian ports serve your market. The lead-time estimates tell you what transit time to expect.
Fig 8.1 HYDERABAD ICD handles $568K — top 8 Indian origin ports by trade value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one Indian port. Bar length = USD value. The largest ports handle the majority of trade.
Fig 8.2 NEWARK APT/NEW YORK is the #1 global destination port — top 16 by USD value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one destination port worldwide. Bar length = USD value received from India.
§8.1 Reference transit times for key India → global corridors
| Route | Mode | Transit time | Notes |
|---|---|---|---|
| NHAVA SHEVA SEA (JNPT) → US East Coast | Sea | 22–28 days | Via Suez; 2–3 transshipments typical |
| NHAVA SHEVA SEA (JNPT) → Lagos (Nigeria) | Sea | 18–24 days | Direct liner service available |
| MUMBAI AIR (SAHAR) → New York JFK | Air | 3–5 days | Direct cargo; cold-chain available |
| MUNDRA SEA → Rotterdam | Sea | 20–26 days | Via Suez; Hamburg also served |
| HYDERABAD AIR → London Heathrow | Air | 2–4 days | Pharma-grade cargo corridor |
| CHENNAI SEA → Chittagong (Bangladesh) | Sea | 7–12 days | Short-sea route; high frequency |
| RAXAUL → Birgunj (Nepal) | Road | 1–2 days | Land border crossing |
| NHAVA SHEVA SEA (JNPT) → Mombasa (Kenya) | Sea | 14–20 days | Direct or via Colombo hub |
Table 8.1 — Reference times based on standard shipping corridors. Air = 2–5 days; sea = 7–28 days; road = 1–2 days. Add 3–7 days for customs clearance at destination.
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Trade corridors — origin port to mode of transport to destination region
KEY TAKEAWAY
ICD dominates at 33% of shipments. The alluvial traces every dollar from Indian origin port through transport mode to destination region.
ICD
$573K
48.5% of USD · 33.3% of ships
SEA
$544K
46.0% of USD · 58.3% of ships
AIR
$64K
5.4% of USD · 8.3% of ships
Fig 8.3 The dominant corridor is HYDERABAD ICD → Sea → N. America ($568K).
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian origin ports. Middle = transport mode. Right = destination region. Ribbon thickness = USD value; color = mode. Follow the thickest ribbons to find the highest-value corridors.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market concentration, supply-chain risk, and the dependency patterns that signal where to act
KEY TAKEAWAY
Senegal is the most concentrated destination (HHI 10000, 1 suppliers). Singapore is the most competitive (HHI 10000).
S FOR SUPPLIERS
The HHI barbell shows where competitors have locked up a market (concentrated = poaching opportunity) vs where you must compete on quality (fragmented). The slope chart reveals who is gaining ground.
B FOR BUYERS
The HHI barbell tells you whether your country has enough supplier options. If concentrated (red zone), you have fewer alternatives.
Fig 9.1 Senegal (HHI 10,000) is the most concentrated — United States (HHI 2,888) is the most competitive.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
What is HHI? The Herfindahl-Hirschman Index measures how concentrated a market is among its suppliers. It ranges from 0 to 10,000. Below 1,500 (green zone) = many suppliers compete openly — healthy, competitive market with low risk. 1,500–2,500 (yellow zone) = a few suppliers hold significant share — moderate concentration. Above 2,500 (red zone) = one or two suppliers dominate the market — high risk for buyers who may lose supply, and hard to break into for new suppliers. Conclusion: 8 of 9 destination markets are concentrated (red zone). 0 are competitive (green zone). Buyers in red-zone markets should urgently qualify a second Indian supplier to reduce dependency risk.
§9.1 Single-source dependencies
| Buyer | Country | Sole supplier | USD | Ships | Risk |
|---|---|---|---|---|---|
| GRANULES USA | United States | GRANULES INDIA LTD | $343K | 4 | HIGH |
| TIME-CAP LABS INC | United States | MARKSANS PHARMA … | $176K | 10 | HIGH |
| HHH PHARMACEUTICALS | United States | ELYSIUM PHARMACE… | $164K | 2 | HIGH |
| GRANULES CONSUMER HE… | United States | GRANULES INDIA LTD | $134K | 3 | HIGH |
| PRODOSE INC | United States | ELYSIUM PHARMACE… | $93K | 2 | MEDIUM |
| REED-LANE INC | United States | DRREDDYS LABORAT… | $81K | 1 | MEDIUM |
| OHM LABORATORIES INC | United States | SUN PHARMACEUTIC… | $66K | 5 | MEDIUM |
| YASH PHARMACEUTICALS… | Tanzania | CADILA PHARMACEU… | $33K | 1 | MEDIUM |
Conclusion: 16 buyers depend on exactly one Indian supplier, representing $1.2M in trade. For suppliers: each row is a competitor’s locked-in customer you can target.
§9.2 Multi-source resilience
| Buyer | Country | Suppliers | USD | Dominant | Resilience |
|---|
Conclusion: 0 of these buyers have HIGH resilience (3+ active suppliers). These are the hardest accounts to win but safest partners for long-term contracts.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market entry playbook and risk landscape by destination country
KEY TAKEAWAY
15 target markets with specific entry approaches. Large suppliers: focus on regulated Tier 1 markets. Small/mid-size: start with Tier 2–3 (low barrier, growing demand).
§9.3 Sourcing recommendations · Table 9.1
| Country | Tier | Lead | Price | Risk | Entry approach |
|---|---|---|---|---|---|
| United States | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Tanzania | Tier 3 (emerging) | 14–28 days (sea) | $0.10–$1/unit | LOW | First-mover advantage |
| Senegal | Tier 3 (emerging) | 14–28 days (sea) | $0.01–$0.10/unit | LOW | First-mover advantage |
| France | Tier 3 (emerging) | 14–28 days (sea) | $0.10–$1/unit | LOW | First-mover advantage |
| Tajikistan | Tier 3 (emerging) | 14–28 days (sea) | $0.10–$1/unit | LOW | First-mover advantage |
| United Arab Emirates | Tier 3 (emerging) | 14–28 days (sea) | $0.10–$1/unit | LOW | First-mover advantage |
| Afghanistan | Tier 3 (emerging) | 14–28 days (sea) | $0.01–$0.10/unit | LOW | First-mover advantage |
| Singapore | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Maldives | Tier 3 (emerging) | 14–28 days (sea) | $0.01–$0.10/unit | LOW | First-mover advantage |
For suppliers: Tier 1 markets (US, UK, France) require regulatory investment but offer premium pricing. Tier 3 markets (emerging) have low barriers — ideal for first-time exporters. For buyers: Use the price band and lead time to benchmark your current supplier’s terms.
Fig 9.2 0 markets in the Growth Opportunity zone (competitive + growing). 7 in Fragile Dependency (concentrated + shrinking).
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bubble = one destination. X-axis = HHI (concentration). Y-axis = growth %. Bubble size = USD. Green zone (top-left) = Growth Opportunity — competitive markets that are growing, best for new entrants. Red zone (bottom-right) = Fragile Dependency — concentrated + shrinking, high supply-chain risk. Conclusion: Key markets are the top growth opportunities.
09
PART V — ACTION
Action Plan & Easy-Entry Markets
12 prioritised actions + 8 low-competition destination countries for small & mid-size suppliers
KEY TAKEAWAY
Quick Wins: execute this quarter. Big Bets: plan for next 6–12 months. Plus 8 countries with ≤5 Indian suppliers — the best entry points for SMEs.
S
FOR SUPPLIERS
| ID | Action | Timing | Impact |
|---|---|---|---|
| A1 | Pitch top single-source buyer in United States | This Q | HIGH |
| A2 | Offer alternative to top multi-source buyer | This Q | HIGH |
| A3 | Audit Senegal lock-ins (HHI 10000) | This Q | MED |
| A5 | Enter Tanzania (1 suppliers) | This Q | HIGH |
| A6 | Enter Senegal (1 suppliers) | This Q | MED |
| A8 | Build Tanzania distribution | 6–12m | HIGH |
| A9 | Bundle injection/infusion catalog for premium markets | 6–12m | MED |
B
FOR BUYERS
| ID | Action | Timing | Impact |
|---|---|---|---|
| A4 | Monitor rising exporters (climbers) | This Q | MED |
| A7 | Register for United States tenders | 6–12m | HIGH |
| A10 | Track quarterly HHI shifts across key destinations | This Q | LOW |
| A11 | Map competitor buyer portfolios quarterly | This Q | MED |
| A12 | Qualify second source for single-source buyers | This Q | MED |
§9.4 Easy-entry markets — 8 countries with ≤5 Indian suppliers
| # | Country | Region | Suppliers | Q4 USD | Growth | Barrier | Why this is easy |
|---|---|---|---|---|---|---|---|
| 1 | Tanzania | Africa | 1 | $33K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 2 | Senegal | Africa | 1 | $18K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 3 | France | Other | 1 | $11K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 4 | Tajikistan | Asia | 1 | $3K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 5 | United Arab Emirates | Other | 1 | $3K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 6 | Afghanistan | Asia | 1 | $2K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 7 | Singapore | Asia | 1 | $165 | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 8 | Maldives | Asia | 1 | $0 | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
This report covers 48 2025-Q4 Guaifenesin shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/guaifenesin
10
PART VI — EVIDENCE REGISTER
Comprehensive Shipment Records by Region
Authoritative source behind all analytics in this report — every shipment appears exactly once
KEY TAKEAWAY
This section contains every one of the 48 2025-Q4 guaifenesin shipments, organised by Region → Exporter → Shipment rows. No row is duplicated.
S FOR SUPPLIERS
Jump to any destination country to see exactly who your competitors ship to, what they charge, through which port, and how often.
B FOR BUYERS
Jump to your country to see every Indian guaifenesin shipment that arrived in 2025-Q4: supplier, price, dosage, port.
§10.1 Global totals
SHIPMENTS
48
across all regions
TOTAL USD
$1.18M
2025-Q4 FOB value
UNITS
17.7M
tablets, capsules, etc.
SUPPLIERS
13
Indian exporters
BUYERS
17
global importers
COUNTRIES
9
destinations
§10.2 Regional breakdown
§10.3 Key insights from the data
Africa is the largest region at $51K (4.3%), spanning 2 countries.
13 Indian suppliers shipped to 17 buyers across 9 countries — average shipment value $25K.
Top 0 markets: .
Every row below is real customs data — date, importer, dosage, brand, quantity, unit price, total USD, origin port, destination port, and transport mode.
§10.4 How to read a country page
1
6 KPI cards — shipments, USD, qty, exporters, importers, avg unit price.
2
4 mini-lists — top exporters, importers, dosages, monthly trend.
3
Shipment register — every row grouped by exporter. No row is duplicated or omitted.
10
PART VI — DRILL-DOWN · AFRICA
Region: Africa
2 countries · 4 shipments · $51K · 2 Indian suppliers · 2 buyers
SHIPMENTS
4
USD
$51K
COUNTRIES
2
SUPPLIERS
2
BUYERS
2
HHI
5,412
concentrated
Top 2 destination countries in Africa
1
Tanzania (64.4%)
$33K
2
Senegal (35.6%)
$18K
Top 2 Indian suppliers into Africa
1
CADILA PHARMACEUTICALS LTD
$33K
2
ALFA BIOMED INDIA PVT LTD
$18K
Top 2 Africa importers
1
YASH PHARMACEUTICALS LTD · Tanzania
$33K
2
DUOPHARM · Senegal
$18K
Top 3 dosage forms
1
expectorant
$33K
2
Suspension
$17K
3
Unknown
$886.10
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 1 | $33K | $33K |
| Nov | 3 | $18K | $6K |
| Dec | 0 | $0.0000 | — |
Shipment register · 4 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — CADILA PHARMACEUTICALS LTD · 1 shipments · $33K | |||||||||||
| 1 | Oct 2025 | YASH PHARMACEUTICALS LTD | Tanzania | expectorant | 44.4K | NOS | $0.739 | $33K | MUNDRA SEA | DAR ES SALAAM | SEA |
| SUPPLIER #2 — ALFA BIOMED INDIA PVT LTD · 3 shipments · $18K | |||||||||||
| 2 | Nov 2025 | DUOPHARM | Senegal | Suspension | 140.0K | NOS | $0.086 | $12K | NHAVA SHEVA SEA (JNPT) | Dakar | SEA |
| 3 | Nov 2025 | DUOPHARM | Senegal | Suspension | 60.0K | NOS | $0.086 | $5K | NHAVA SHEVA SEA (JNPT) | Dakar | SEA |
| 4 | Nov 2025 | DUOPHARM | Senegal | 10.0K | NOS | $0.089 | $886.10 | NHAVA SHEVA SEA (JNPT) | Dakar | SEA | |
10
PART VI — DRILL-DOWN · ASIA
Region: Asia
5 countries · 7 shipments · $9K · 5 Indian suppliers · 4 buyers
SHIPMENTS
7
USD
$9K
COUNTRIES
5
SUPPLIERS
5
BUYERS
4
HHI
3,351
concentrated
Top 5 destination countries in Asia
1
Tajikistan (38.3%)
$3K
2
United Arab Emirates (36.6%)
$3K
3
Afghanistan (23.3%)
$2K
4
Singapore (1.8%)
$164.88
5
Maldives · Maldives
$0.0000
Top 5 Indian suppliers into Asia
1
XIEON LIFE SCIENCES PVT LTD
$3K
2
JOINHUB PHARMA LLP
$3K
3
LABORATE PHARMACEUTICALS INDIA LTD
$2K
4
SANITAS MEDTECH INSTITUTE PVT LTD
$164.88
5
MOTHER INDIA TRADERS
$0.0000
Top 3 Asia importers
1
SUCCESS INTER LINK PTE LTD · Singapore
$164.88
2
AGALU · Maldives
$0.0000
3
K.D.M SHOP NO .01 (BN · Maldives
$0.0000
Top 3 dosage forms
1
Syrup
$7K
2
Tablet
$2K
3
Drops
$0.0000
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 2 | $7K | $3K |
| Nov | 4 | $164.88 | $41.22 |
| Dec | 1 | $2K | $2K |
Shipment register · 7 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — XIEON LIFE SCIENCES PVT LTD · 1 shipments · $3K | |||||||||||
| 1 | Oct 2025 | UNLISTED BUYER | Tajikistan | Syrup | 15.0K | NOS | $0.231 | $3K | SONEPAT ICD | TJDYU | ICD |
| SUPPLIER #2 — JOINHUB PHARMA LLP · 1 shipments · $3K | |||||||||||
| 2 | Oct 2025 | UNLISTED BUYER | United Arab Emirates | Syrup | 10.0K | PCS | $0.331 | $3K | NHAVA SHEVA SEA (JNPT) | Baghdad | SEA |
| SUPPLIER #3 — LABORATE PHARMACEUTICALS INDIA LTD · 1 shipments · $2K | |||||||||||
| 3 | Dec 2025 | UNLISTED BUYER | Afghanistan | Tablet | 30.1K | NOS | $0.070 | $2K | PATLI ICD | KABUL | ICD |
| SUPPLIER #4 — SANITAS MEDTECH INSTITUTE PVT LTD · 1 shipments · $164.88 | |||||||||||
| 4 | Nov 2025 | SUCCESS INTER LINK PTE LTD | Singapore | Tablet | 20 | NOS | $8.24 | $164.88 | MUMBAI AIR (SAHAR) | SINGAPORE | AIR |
| SUPPLIER #5 — MOTHER INDIA TRADERS · 3 shipments · $0.0000 | |||||||||||
| 5 | Nov 2025 | AGALU | Maldives | Drops | 480 | NOS | $0.0000 | $0.0000 | CHENNAI SEA | Male | SEA |
| 6 | Nov 2025 | K.D.M SHOP NO .01 (BN | Maldives | Drops | 384 | NOS | $0.0000 | $0.0000 | CHENNAI SEA | Male | SEA |
| 7 | Nov 2025 | AGALU | Maldives | Drops | 480 | NOS | $0.0000 | $0.0000 | CHENNAI SEA | Male | SEA |
10
PART VI — DRILL-DOWN · EUROPE
Region: Europe
1 countries · 1 shipments · $11K · 1 Indian suppliers · 1 buyers
SHIPMENTS
1
USD
$11K
COUNTRIES
1
SUPPLIERS
1
BUYERS
1
HHI
10,000
concentrated
Top 1 destination countries in Europe
1
France (100.0%)
$11K
Top 1 Indian suppliers into Europe
1
ALFA BIOMED INDIA PVT LTD
$11K
Top 1 Europe importers
1
PLANET PHARMAZAC DU GRAND LAUNAY · France
$11K
Top 1 dosage forms
1
Tablet
$11K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 1 | $11K | $11K |
| Nov | 0 | $0.0000 | — |
| Dec | 0 | $0.0000 | — |
Shipment register · 1 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — ALFA BIOMED INDIA PVT LTD · 1 shipments · $11K | |||||||||||
| 1 | Oct 2025 | PLANET PHARMAZAC DU GRAND LAUNAY | France | Tablet | 49.0K | NOS | $0.233 | $11K | NHAVA SHEVA SEA (JNPT) | Rouen | SEA |
10
PART VI — DRILL-DOWN · AMERICAS
Region: Americas
1 countries · 36 shipments · $1.11M · 6 Indian suppliers · 10 buyers
SHIPMENTS
36
USD
$1.11M
COUNTRIES
1
SUPPLIERS
6
BUYERS
10
HHI
2,888
concentrated
Top 1 destination countries in Americas
1
United States (100.0%)
$1.11M
Top 6 Indian suppliers into Americas
1
GRANULES INDIA LTD
$478K
2
ELYSIUM PHARMACEUTICALS LTD
$278K
3
MARKSANS PHARMA LTD
$199K
4
DRREDDYS LABORATORIES LTD
$81K
5
SUN PHARMACEUTICAL INDUSTRIES LTD
$66K
6
KJD PHARMA PVT LTD
$9K
Top 10 Americas importers
1
GRANULES USA · United States
$343K
2
TIME-CAP LABS INC · United States
$176K
3
HHH PHARMACEUTICALS · United States
$164K
4
GRANULES CONSUMER HEALTH LLC · United States
$134K
5
PRODOSE INC · United States
$93K
6
REED-LANE INC · United States
$81K
7
OHM LABORATORIES INC · United States
$66K
8
TIME-CAP LABSINC 7 MICHAEL AVENUE · United States
$23K
9
PIONEER LIFE SCIENCE LLC · United States
$21K
10
AIRLIE PHARMA · United States
$9K
Top 5 dosage forms
1
Tablet
$798K
2
Other
$159K
3
Unknown
$126K
4
extended-release tablet
$17K
5
Solution
$9K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 13 | $210K | $16K |
| Nov | 9 | $346K | $38K |
| Dec | 14 | $555K | $40K |
Shipment register · 36 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — GRANULES INDIA LTD · 7 shipments · $478K | |||||||||||
| 1 | Dec 2025 | GRANULES CONSUMER HEALTH LLC | United States | Tablet | 2.0M | NOS | $0.024 | $47K | HYDERABAD ICD | NORFOLK | ICD |
| 2 | Dec 2025 | GRANULES USA | United States | Tablet | 1.9M | NOS | $0.044 | $84K | HYDERABAD ICD | NEWARK APT/NEW YORK | ICD |
| 3 | Dec 2025 | GRANULES USA | United States | Tablet | 1.9M | NOS | $0.023 | $42K | HYDERABAD ICD | NEWARK APT/NEW YORK | ICD |
| 4 | Dec 2025 | GRANULES USA | United States | Tablet | 980.0K | NOS | $0.044 | $43K | HYDERABAD ICD | NEWARK APT/NEW YORK | ICD |
| 5 | Dec 2025 | GRANULES CONSUMER HEALTH LLC | United States | Tablet | 1.9M | NOS | $0.024 | $44K | HYDERABAD ICD | NORFOLK | ICD |
| 6 | Dec 2025 | GRANULES CONSUMER HEALTH LLC | United States | Tablet | 1.8M | NOS | $0.024 | $44K | HYDERABAD ICD | NORFOLK | ICD |
| 7 | Dec 2025 | GRANULES USA | United States | Tablet | 3.8M | NOS | $0.045 | $174K | HYDERABAD ICD | NEWARK APT/NEW YORK | ICD |
| SUPPLIER #2 — ELYSIUM PHARMACEUTICALS LTD · 5 shipments · $278K | |||||||||||
| 8 | Oct 2025 | HHH PHARMACEUTICALS | United States | Tablet | 128 | NOS | $323.10 | $41K | MUNDRA SEA | NEW YORK | SEA |
| 9 | Oct 2025 | PIONEER LIFE SCIENCE LLC | United States | Tablet | 64 | NOS | $327.49 | $21K | MUNDRA SEA | New York | SEA |
| 10 | Nov 2025 | HHH PHARMACEUTICALS | United States | Other | 408 | NOS | $301.68 | $123K | MUNDRA SEA | New York | SEA |
| 11 | Nov 2025 | PRODOSE INC | United States | 168 | NOS | $333.25 | $56K | MUNDRA SEA | New York | SEA | |
| 12 | Nov 2025 | PRODOSE INC | United States | 115 | NOS | $319.18 | $37K | MUNDRA SEA | New York | SEA | |
| SUPPLIER #3 — MARKSANS PHARMA LTD · 12 shipments · $199K | |||||||||||
| 13 | Oct 2025 | TIME-CAP LABSINC 7 MICHAEL AVENUE | United States | Tablet | 3.3K | NOS | $4.18 | $14K | NHAVA SHEVA SEA (JNPT) | New York | SEA |
| 14 | Oct 2025 | TIME-CAP LABS INC | United States | Tablet | 7.7K | NOS | $2.30 | $18K | NHAVA SHEVA SEA (JNPT) | New York | SEA |
| 15 | Oct 2025 | TIME-CAP LABS INC | United States | Tablet | 7.3K | NOS | $2.30 | $17K | NHAVA SHEVA SEA (JNPT) | New York | SEA |
| 16 | Oct 2025 | TIME-CAP LABSINC 7 MICHAEL AVENUE | United States | Tablet | 11.1K | NOS | $0.823 | $9K | NHAVA SHEVA SEA (JNPT) | Newark | SEA |
| 17 | Nov 2025 | TIME-CAP LABS INC | United States | Tablet | 1.7K | NOS | $10.50 | $18K | NHAVA SHEVA SEA (JNPT) | Newark | SEA |
| 18 | Nov 2025 | TIME-CAP LABS INC | United States | 15.1K | NOS | $1.48 | $22K | NHAVA SHEVA SEA (JNPT) | New York | SEA | |
| 19 | Nov 2025 | TIME-CAP LABS INC | United States | 7.7K | NOS | $1.45 | $11K | NHAVA SHEVA SEA (JNPT) | New York | SEA | |
| 20 | Nov 2025 | TIME-CAP LABS INC | United States | extended-release tablet | 7.6K | NOS | $2.30 | $17K | NHAVA SHEVA SEA (JNPT) | Newark | SEA |
| 21 | Nov 2025 | TIME-CAP LABS INC | United States | Tablet | 30.7K | NOS | $0.822 | $25K | NHAVA SHEVA SEA (JNPT) | Newark | SEA |
| 22 | Dec 2025 | TIME-CAP LABS INC | United States | Tablet | 7.6K | NOS | $2.34 | $18K | NHAVA SHEVA SEA (JNPT) | New York | SEA |
| 23 | Dec 2025 | TIME-CAP LABS INC | United States | Tablet | 7.7K | NOS | $2.33 | $18K | NHAVA SHEVA SEA (JNPT) | Newark | SEA |
| 24 | Dec 2025 | TIME-CAP LABS INC | United States | Tablet | 7.7K | NOS | $1.50 | $12K | NHAVA SHEVA SEA (JNPT) | Newark | SEA |
| SUPPLIER #4 — DRREDDYS LABORATORIES LTD · 1 shipments · $81K | |||||||||||
| 25 | Oct 2025 | REED-LANE INC | United States | Tablet | 2.2M | NOS | $0.037 | $81K | HYDERABAD ICD | NEWARK | ICD |
| SUPPLIER #5 — SUN PHARMACEUTICAL INDUSTRIES LTD · 5 shipments · $66K | |||||||||||
| 26 | Nov 2025 | OHM LABORATORIES INC | United States | Other | 700.4K | NOS | $0.051 | $36K | DELHI AIR | NEWARK, NJ | AIR |
| 27 | Dec 2025 | OHM LABORATORIES INC | United States | Tablet | 7.5K | NOS | $2.49 | $19K | DELHI AIR | NEW YORK | AIR |
| 28 | Dec 2025 | OHM LABORATORIES INC | United States | Tablet | 29.8K | NOS | $0.030 | $892.63 | NHAVA SHEVA SEA (JNPT) | New York | SEA |
| 29 | Dec 2025 | OHM LABORATORIES INC | United States | Tablet | 27.0K | NOS | $0.030 | $807.38 | NHAVA SHEVA SEA (JNPT) | New York | SEA |
| 30 | Dec 2025 | OHM LABORATORIES INC | United States | Tablet | 1.9K | NOS | $4.81 | $9K | DELHI AIR | NEWARK, NJ | AIR |
| SUPPLIER #6 — KJD PHARMA PVT LTD · 6 shipments · $9K | |||||||||||
| 31 | Oct 2025 | AIRLIE PHARMA | United States | Solution | 8.2K | NOS | $0.224 | $2K | HYDERABAD ICD | SAVANNAH | ICD |
| 32 | Oct 2025 | AIRLIE PHARMA | United States | Solution | 4.1K | NOS | $0.447 | $2K | HYDERABAD ICD | SAVANNAH | ICD |
| 33 | Oct 2025 | AIRLIE PHARMA | United States | Solution | 2.0K | NOS | $0.671 | $1K | HYDERABAD ICD | SAVANNAH | ICD |
| 34 | Oct 2025 | AIRLIE PHARMA | United States | Solution | 2.0K | NOS | $0.671 | $1K | HYDERABAD ICD | SAVANNAH | ICD |
| 35 | Oct 2025 | AIRLIE PHARMA | United States | Solution | 2.0K | NOS | $0.671 | $1K | HYDERABAD ICD | SAVANNAH | ICD |
| 36 | Oct 2025 | AIRLIE PHARMA | United States | Solution | 4.0K | NOS | $0.447 | $2K | HYDERABAD ICD | SAVANNAH | ICD |
10
PART VI — EVIDENCE REGISTER
Indian Supplier Directory
All 13 Indian guaifenesin exporters — complete list ranked by USD
KEY TAKEAWAY
This directory lists every Indian company that shipped guaifenesin in 2025-Q4.
S FOR SUPPLIERS
Find yourself and your competitors. Compare shipment count, USD, and destination regions.
B FOR BUYERS
Search for potential Indian suppliers. Filter by dosage form and destination region.
| # | Supplier | City | Ships | USD | Dosage forms | Primary regions |
|---|---|---|---|---|---|---|
| 1 | GRANULES INDIA LTD | HYDERABAD | 7 | $478K | Tablet | Americas |
| 2 | ELYSIUM PHARMACEUTICALS LTD | DIST. VADODARA | 5 | $278K | Tablet, Other | Americas |
| 3 | MARKSANS PHARMA LTD | MUMBAI | 12 | $199K | Tablet, extended-release tablet | Americas |
| 4 | DRREDDYS LABORATORIES LTD | MEDCHEL MALKAJGIRI DIST | 1 | $81K | Tablet | Americas |
| 5 | SUN PHARMACEUTICAL INDUSTRIES LTD | MUMBAI | 5 | $66K | Other, Tablet | Americas |
| 6 | CADILA PHARMACEUTICALS LTD | AHMEDABAD | 1 | $33K | expectorant | Africa |
| 7 | ALFA BIOMED INDIA PVT LTD | PUNE/MAH. | 4 | $30K | Tablet, Suspension | Europe, Africa |
| 8 | KJD PHARMA PVT LTD | BIDAR | 6 | $9K | Solution | Americas |
| 9 | XIEON LIFE SCIENCES PVT LTD | KARNAL | 1 | $3K | Syrup | Asia |
| 10 | JOINHUB PHARMA LLP | AHMEDABAD | 1 | $3K | Syrup | Asia |
| 11 | LABORATE PHARMACEUTICALS INDIA LTD | HIMANCHAL PRADESH | 1 | $2K | Tablet | Asia |
| 12 | SANITAS MEDTECH INSTITUTE PVT LTD | Narhen | 1 | $164.88 | Tablet | Asia |
| 13 | MOTHER INDIA TRADERS | CHENNAI | 3 | $0.0000 | Drops | Asia |
10
PART VI — EVIDENCE REGISTER
Global Buyer Directory
All 16 global guaifenesin importers — complete list ranked by USD
KEY TAKEAWAY
This directory lists every company that imported Indian guaifenesin in 2025-Q4.
S FOR SUPPLIERS
Search for potential customers by country and dosage form.
B FOR BUYERS
Find your company and see which Indian supplier serves you.
| # | Buyer | Country | Ships | USD | Primary supplier | Dosage forms |
|---|---|---|---|---|---|---|
| 1 | GRANULES USA | United States | 4 | $343K | GRANULES INDIA LTD | Tablet |
| 2 | TIME-CAP LABS INC | United States | 10 | $176K | MARKSANS PHARMA LTD | Tablet, extended-release tablet |
| 3 | HHH PHARMACEUTICALS | United States | 2 | $164K | ELYSIUM PHARMACEUTIC… | Tablet, Other |
| 4 | GRANULES CONSUMER HEALTH LLC | United States | 3 | $134K | GRANULES INDIA LTD | Tablet |
| 5 | PRODOSE INC | United States | 2 | $93K | ELYSIUM PHARMACEUTIC… | |
| 6 | REED-LANE INC | United States | 1 | $81K | DRREDDYS LABORATORIE… | Tablet |
| 7 | OHM LABORATORIES INC | United States | 5 | $66K | SUN PHARMACEUTICAL I… | Other, Tablet |
| 8 | YASH PHARMACEUTICALS LTD | Tanzania | 1 | $33K | CADILA PHARMACEUTICA… | expectorant |
| 9 | TIME-CAP LABSINC 7 MICHAEL AVENUE | United States | 2 | $23K | MARKSANS PHARMA LTD | Tablet |
| 10 | PIONEER LIFE SCIENCE LLC | United States | 1 | $21K | ELYSIUM PHARMACEUTIC… | Tablet |
| 11 | DUOPHARM | Senegal | 3 | $18K | ALFA BIOMED INDIA PV… | Suspension |
| 12 | PLANET PHARMAZAC DU GRAND LAUNAY | France | 1 | $11K | ALFA BIOMED INDIA PV… | Tablet |
| 13 | AIRLIE PHARMA | United States | 6 | $9K | KJD PHARMA PVT LTD | Solution |
| 14 | SUCCESS INTER LINK PTE LTD | Singapore | 1 | $164.88 | SANITAS MEDTECH INST… | Tablet |
| 15 | AGALU | Maldives | 2 | $0.0000 | MOTHER INDIA TRADERS | Drops |
| 16 | K.D.M SHOP NO .01 (BN | Maldives | 1 | $0.0000 | MOTHER INDIA TRADERS | Drops |
This report covers 48 2025-Q4 Guaifenesin shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/guaifenesin
Talk to our trade analyst
Need a custom guaifenesin report or a deeper dive into any market? Our team is ready.
WhatsApp: +91 95950 78788 · transdatanexus.com
PHARMA TRADE INTELLIGENCE
Thank you for reading
This report is part of the TransData Nexus Pharma Trade Intelligence series, covering 366 pharmaceutical products exported from India.
Every figure is grounded in real commercial trade records — official customs filings and licensed databases. No surveys, no estimates, no fake data.
Need a custom report?
We can generate intelligence for any pharmaceutical product, any time period, any combination of source and destination countries.
Want deeper analysis?
Our team provides competitive intelligence, market entry strategy, and supply chain due diligence for pharma importers and exporters.
Scan for product page
WhatsApp: +91 95950 78788
Email: info@transdatanexus.com
Web: https://transdatanexus.com/pharmaceutical/guaifenesin
© 2026 TransData Nexus. All rights reserved. This report is provided for informational purposes only.
Data sourced from official customs filings and licensed commercial trade databases.
Reproduction without permission is prohibited.
Explore the full Guaifenesin product page
Live data, supplier directory, price trends, and trade route analysis